Literature DB >> 32542593

Loss of Estrogen Efficacy Against Hippocampus Damage in Long-Term OVX Mice Is Related to the Reduction of Hippocampus Local Estrogen Production and Estrogen Receptor Degradation.

Yulong Ma1,2, Min Liu1, Lifang Yang3, Lixia Zhang4, Hang Guo5, Pei Qin6, Wugang Hou7.   

Abstract

Postmenopausal women experience a higher risk for neurodegenerative diseases, including cognitive impairment and ischemic stroke. Many preclinical studies have indicated that estrogen replacement therapy (ERT) may provide protective effects against these neurological diseases. However, the results of Women's Health Initiative (WHI) studies have led to the proposal of "critical period hypothesis," which states that there is a precise window of opportunity for administering beneficial hormone therapy following menopause. However, the underlying molecular mechanisms require further characterization. Here, we explored the effects of ERT on cognition decline and global cerebral ischemia (GCI)-induced hippocampal neuronal damage in mice that had experienced both short-term (ovariectomized (OVX) 1 week) and long-term (OVX 10 weeks) estrogen deprivation. We also further explored the concentration of 17β-estradiol (E2) in the circulation and hippocampus and the expression of aromatase and estrogen receptors (ERα, ERα-Ser118, and ERβ). We found that the neuroprotective effectiveness of ERT against hippocampus damage exhibited in OVX1w mice was totally absent in OVX10w mice. Interestingly, the concentration of hippocampal E2 was irreversibly reduced in OVX10w mice, which was related to the decrease of aromatase expression in the hippocampus. In addition, long-term estrogen deprivation (LTED) led to a decrease in estrogen receptor proteins in the hippocampus. Thus, we concluded that the loss of ERT neuroprotection against hippocampus injury in LTED mice was related to the reduction in hippocampus E2 production and estrogen receptor degradation. These results provide several intervention targets to restore the effectiveness of ERT neuroprotection in elderly post-menopausal women.

Entities:  

Keywords:  Critical period hypothesis; Estrogen replacement treatment (ERT); Hippocampus damage; Hippocampus-derived estrogen; Long-term estrogen deprivation (LTED); Neuroprotection

Mesh:

Substances:

Year:  2020        PMID: 32542593     DOI: 10.1007/s12035-020-01960-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  51 in total

Review 1.  Sex differences in Parkinson's disease and other movement disorders.

Authors:  Kara M Smith; Nabila Dahodwala
Journal:  Exp Neurol       Date:  2014-03-28       Impact factor: 5.330

Review 2.  Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's.

Authors:  Bhagu R Bhavnani
Journal:  J Steroid Biochem Mol Biol       Date:  2003-06       Impact factor: 4.292

Review 3.  Premature menopause or early menopause: long-term health consequences.

Authors:  Lynne T Shuster; Deborah J Rhodes; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca
Journal:  Maturitas       Date:  2009-09-05       Impact factor: 4.342

Review 4.  Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity.

Authors:  Walter A Rocca; Brandon R Grossardt; Lynne T Shuster
Journal:  Brain Res       Date:  2010-10-18       Impact factor: 3.252

Review 5.  The effects of estrogen in ischemic stroke.

Authors:  Edward C Koellhoffer; Louise D McCullough
Journal:  Transl Stroke Res       Date:  2012-12-07       Impact factor: 6.829

6.  Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.

Authors:  W A Rocca; J H Bower; D M Maraganore; J E Ahlskog; B R Grossardt; M de Andrade; L J Melton
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

7.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

8.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

Review 10.  Hormone therapy and cognitive function: is there a critical period for benefit?

Authors:  P M Maki
Journal:  Neuroscience       Date:  2006-02-20       Impact factor: 3.590

View more
  1 in total

1.  Ovarian status modulates endocrine and neuroinflammatory responses to a murine mammary tumor.

Authors:  Lindsay D Strehle; Kathryn L G Russart; Valerie A Burch; Corena V Grant; Leah M Pyter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-08-22       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.